Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fast-acting insulin aspart vs NovoRapid with insulin degludec in type 2 diabetes
2016-000878-38Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c. Started May 2017; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-000878-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000878-38.